Oligopeptide lyophilisate, their preparation and use

Details Oligopeptide lyophilisate, their preparation and use Oligopeptide lyophilisate, their preparation and use

2005-03-08

2005-03-08

Minnifield, Nita (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S184100, C424S185100, C424S193100, C514S015800, C514S014800, C514S800000, C514S255030, C514S012200, C514S013800, C530S300000, C530S313000, C530S328000, C930S110000, C930S130000

Reexamination Certificate

active

06863891

ABSTRACT:
A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% v/v, the solution is transferred to water and freeze dried.

REFERENCES:
patent: 3816386 (1974-06-01), Hedlund et al.
patent: 4372884 (1983-02-01), Brown et al.
patent: 4512923 (1985-04-01), Flegel et al.
patent: 4565804 (1986-01-01), Rivier et al.
patent: 4693993 (1987-09-01), Stewart et al.
patent: 4701499 (1987-10-01), Kornreich et al.
patent: 4711877 (1987-12-01), Moore
patent: 4716242 (1987-12-01), Engel et al.
patent: 4800191 (1989-01-01), Schally et al.
patent: 4908475 (1990-03-01), Callahan et al.
patent: 5198533 (1993-03-01), Schally et al.
patent: 5204335 (1993-04-01), Sauerbier et al.
patent: 5268360 (1993-12-01), Yoshikawa et al.
patent: 5446033 (1995-08-01), Engel et al.
patent: 5663145 (1997-09-01), Engel et al.
patent: 5728738 (1998-03-01), Engel et al.
patent: 5750131 (1998-05-01), Wichert et al.
patent: 5773032 (1998-06-01), Engel et al.
patent: 5945128 (1999-08-01), Deghenghi
patent: 5968895 (1999-10-01), Gefter et al.
patent: 5998377 (1999-12-01), Engel et al.
patent: 6022860 (2000-02-01), Engel et al.
patent: 6054555 (2000-04-01), Engel et al.
patent: 6106805 (2000-08-01), Engel et al.
patent: 6297379 (2001-10-01), Furuya et al.
patent: 6340686 (2002-01-01), Furuya et al.
patent: 6585982 (2003-07-01), Grondahl et al.
patent: 6627609 (2003-09-01), Bernd et al.
patent: 6635740 (2003-10-01), Enright et al.
patent: 20010041672 (2001-11-01), Stockemann et al
patent: 20020198155 (2002-12-01), Stockmann et al
patent: 20030100509 (2003-05-01), Sarlikiotis et al.
patent: 141 996 (1980-06-01), None
patent: 0 175 506 (1986-03-01), None
patent: 0 268 066 (1988-05-01), None
patent: 0 277 829 (1988-08-01), None
patent: 88-308573 (1988-09-01), None
patent: 0 299 402 (1989-01-01), None
patent: 61-87695 (1986-05-01), None
patent: 63-201199 (1988-08-01), None
patent: 05-000963 (1991-10-01), None
patent: 64-034997 (1999-06-01), None
patent: WO 9113092 (1991-09-01), None
patent: WO 9116038 (1991-10-01), None
patent: WO 9119743 (1991-12-01), None
Reissmann et al, Human Reproduction, 1995, 10/8:1974-1981.*
Rongieres-Bertrand et al, Human Reproduction, 1999, 14/3:683-688.*
Ludwig et al, Arch. Gynecol. Obstet., 2000, 264:29-32.*
Niwa et al, J. Chromatography, 1999, 729:245-253.*
Albano et al, Fertility and Sterility, 1998, 70/2:357-359.*
Reissmann et al, J. Cancer Res. Clin. Oncol., 1992, 118:44-49.*
Albano et al, Human Reproduction, 1996, 11/10:2114-2118.*
Oliveness et al, Fertility and Sterility, 2000, 73/2:314-320.*
Tavaniotou et al, Human Reproduction, 2001, 16/4:663-667.*
Olivennes et al, Infertility and Reproductive Medicine Clinics of North America, 2001, 12/1:119-128.*
Albano et al, Human Reproduction, 2000, 15/3:526-531.*
Olivennes et al, Fertility and Sterility, 1994, 62/3:468-476.*
Felberbaum et al, Human Reproduction, 2000, 15/5:1015-1020.*
Olivennes et al, Human Reproduction Update 2000, 6/4:313-317 □ □.*
Felberbaum et al, Eur. J. Obstet. & Gyn. and Reproductive Biology, 1995, 61:151-155.*
Diedrich et al, Human Reproduction, 1994, 9/5:788-791.*
Klingmuller et al, Acta Endocrinologica, 1993, 128:15-18.*
Reissmann et al, Human Reproduction, 1994, 9/5:767-769.*
Beyzarov et al, Drug Topics, Oct. 2000, 144/19:28.*
Christin-Maitre et al, Clinical Endocrinology, 2000, 52/6:721-726.*
Mettler et al, Clinical and Experimental Obstet. and Gyn., 2000, 7/2:103-105.*
Nikolettos et al, Eur. J. Obs. and Gyn. and Reproductive Biology, 2001, 97/2:202-207.*
Ortmann et al, Human Reproduction, 2001, 16/4:608-611.*
Wiklund et al, Human Reproduction, 2001, 16/8:1676-1681.*
Craft et al, Human Reproduction, 1999, 14/12:2959-2962.*
Lin et al, Human Reproduction, 1999, 14/4:885-888.*
Ludwig et al, Fertility and Sterility, 2001, 75/1:18-22.*
Felberbaum et al, Human Reproduction, 1999, 14/Suppl. 1:207-221.*
Rabasseda et al, Drugs of the Future, 1999, 24/4:393-403.*
Fraser et al, Trends in Endocrinology and Metabolism, 1994, 5/2:87-93.*
Diedrich et al, Seminars in Reprdouctive Medicine, 2001, 19/3:213-220.*
Kamischke et al., “Gonadal Protection from Radiation by GnRH Antagonist or Recombinant Human FSH: A Controlled Trial in a Male Nonhuman Primate (Macaca fascicularis),”Journal of Endocrinology, vol. 179, pp. 183-194, 2003.
Karashima et al., “Protective Effects of Analogs of Luteinizing Hormone-Releasing Hormone Against Chemotherapy-Induced Testicular Damage in Rats,”Proc. National Academy of Sciences, vol. 85, Apr. 1988, pp. 2329-2333.
Schally et al., “Protective Effects of Analogs of Luteinizing Hormone-Releasing Hormone Against X-Radiation-Induced Testicular Damage in Rats,”Proc. National Academy of Sciences, vol. 84, Feb. 1987, pp. 851-855.
Schally et al., “Current Concept for Improving Treatment of Prostate Cancer Based on Combination of LH-RH Agonists with Other Agents,”Prostate Cancer, Part A: Research, Endocrine Treatment, and Histopathology, 1987, pp. 173-197.
Schally et al., “Antitumor Effects of Analogs of Hypothalamic Hormones in Endocrine-Dependent Cancers,”Proceedings of the Society for Experimental Biology and Medicine, vol. 175, 1984, pp. 259-281.
Szende et al., “Suppression of Meiosis of Male Germ Cells by an Antagonist of Luteinizing Hormone-Releasing Hormone,”Proc. National Academy of Sciences, vol. 87, Feb. 1990, pp. 901-903.
Yoshikazu et al., “Peptide and Antidemential Agent Containing the Same,” JP2273699, Nov. 8, 1990, Abstract only.

Affiliated with

Also associated with

Rating

Oligopeptide lyophilisate, their preparation and use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oligopeptide lyophilisate, their preparation and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligopeptide lyophilisate, their preparation and use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3401836